The incidence of psoriasis during anti-TNF treatment for various clinical conditions has been estimated at 0.6–5.3% [73, 90], and at 1.6–2% in patients who received anti-TNF agents due to IBD [13, 135]. The gene discussed is TNF; the disease is psoriasis.